Get started
Author

F. Michael Yakes

Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress
1997 · F. Michael Yakes, Bennett Van Houten · Proceedings of the National Academy of Sciences · 1,863
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
2011 · F. Michael Yakes, Jason Chen, et al. · Molecular Cancer Therapeutics · 1,338
PDF
PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization
2002 · Incheol Shin, F Michael Yakes, et al. · Nature Medicine · 791
Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
2002 · F Michael Yakes, Wichai Chinratanalab, et al. · PubMed · 611
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
2001 · S L Moulder, F M Yakes, et al. · PubMed · 548
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors
2003 · Roberto Bianco, Incheol Shin, et al. · Oncogene · 448
Hydrogen Peroxide– and Peroxynitrite-Induced Mitochondrial DNA Damage and Dysfunction in Vascular Endothelial and Smooth Muscle Cells
2000 · Scott W. Ballinger, Cam Patterson, et al. · Circulation Research · 442
PDF
Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis
2015 · Daniel J. Anderson, Ronan Le Moigne, et al. · Cancer Cell · 391
PDF
Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases
2009 · Fawn Qian, Stefan Engst, et al. · Cancer Research · 346
Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083)
2015 · Han-Jie Zhou, Jinhai Wang, et al. · Journal of Medicinal Chemistry · 195
ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
2001 · A E Lenferink, D Busse, et al. · PubMed · 181
In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer
2013 · Frauke Bentzien, Marcus Zuzow, et al. · Thyroid · 137
The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma
2017 · Ronan Le Moigne, Blake T. Aftab, et al. · Molecular Cancer Therapeutics · 111
Inhibition of the T790M Gatekeeper Mutant of the Epidermal Growth Factor Receptor by EXEL-7647
2007 · Steven B. Gendreau, Richard Ventura, et al. · Clinical Cancer Research · 89
Mutations associated with base excision repair deficiency and methylation-induced genotoxic stress
2002 · Robert W. Sobol, David E. Watson, et al. · Proceedings of the National Academy of Sciences · 83
PDF
HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer
2002 · C ARTEAGA, S MOULDER, et al. · Seminars in Oncology · 82
Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway
2014 · Peiwen Yu, A. Douglas Laird, et al. · Molecular Cancer Therapeutics · 80
Cyclin-Dependent Kinase Inhibitor P27Kip1 Is Required for Mouse Mammary Gland Morphogenesis and Function
2001 · Rebecca S. Muraoka, Anne E.G. Lenferink, et al. · The Journal of Cell Biology · 78
The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
2015 · Paul Foster, Kyoko Yamaguchi, et al. · Molecular Cancer Therapeutics · 58
PDF
HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer
2002 · Carlos L. Arteaga, Stacy L. Moulder, et al. · Seminars in Oncology · 51
PCR-Based Assays for the Detection and Quantitation of DNA Damage and Repair
1996 · F. Michael Yakes, Yiming Chen, et al. · Springer eBooks · 39
The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors
2012 · Moon H. Kim, Amy Lew Tsuhako, et al. · Bioorganic & Medicinal Chemistry Letters · 26
Functional studies on the anti-pathoangiogenic properties of CM101
1998 · He-Ping Yan, Clint E. Carter, et al. · Angiogenesis · 15
Identification of a novel membrane protein, HP59, with therapeutic potential as a target of tumor angiogenesis.
2001 · C Fu, S Bardhan, et al. · PubMed · 14
CM101 treatment overrides tumor-induced immunoprivilege leading to apoptosis.
2000 · F M Yakes, B D Wamil, et al. · PubMed · 13
Works count: 70
Citation count: 8,029
H-index: 22
I10-index: 25
Year
Topic
Type